Testing the Addition of the Drug Atezolizumab to the Usual Radiation Treatment for Patients With Early Non-small Cell Lung Cancer

NCT04214262 PHASE3 ACTIVE_NOT_RECRUITING

This phase III trial studies how well atezolizumab added to the usual radiation therapy works in treating patients with stage I-IIA non-small cell lung cancer. Immunotherapy with monoclonal antibodies, such as atezolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Radiation therapy, such as stereotactic body radiation therapy, uses special equipment to position a patient and deliver radiation to tumors with high precision. This method can kill tumor cells with fewer doses over a shorter period and cause less damage to normal tissue. Giving atezolizumab and radiation therapy may work better than radiation therapy alone in treating patients with early non-small cell lung cancer.

Details

Lead sponsor	National Cancer Institute (NCI)
Phase	PHASE3
Status	ACTIVE_NOT_RECRUITING
Enrolment	480
Start date	Thu Aug 13 2020 00:00:00 GMT+0000 (Coordinated Universal Time)
Completion	Mon May 01 2028 00:00:00 GMT+0000 (Coordinated Universal Time)

Conditions

• Lung Non-Small Cell Carcinoma
• Stage I Lung Cancer AJCC v8
• Stage II Lung Cancer AJCC v8

Interventions

• Atezolizumab
• Biospecimen Collection
• Computed Tomography
• Fludeoxyglucose F-18
• Positron Emission Tomography
• Quality-of-Life Assessment
• Questionnaire Administration
• Stereotactic Body Radiation Therapy

Countries

United States